SAN MATEO, Calif., Oct. 1, 2025 — Sagimet Biosciences announced that it has dosed the first participants in a Phase 1 pharmacokinetic clinical trial evaluating the combination of its fatty acid synthase (FASN) inhibitor denifanstat with the thyroid hormone receptor beta agonist resmetirom. The open-label study will assess safety, tolerability, drug-drug interactions, and PK profile in approximately 40 healthy adults. Topline results are expected in the first half of 2026.
Science Significance
Denifanstat is a once-daily oral FASN inhibitor that reduces liver fat synthesis and inflammation, while resmetirom is a fat oxidizer that improves lipid metabolism. Together, these complementary mechanisms could provide synergistic benefits in reducing fibrosis and fat accumulation in MASH. Preclinical studies showed improved NAFLD Activity Scores and collagen reduction compared to either drug alone, underscoring the potential scientific breakthrough of combination therapy in advanced liver disease.
Regulatory Significance
The Phase 1 trial is designed to generate the PK and safety data regulators require before advancing to Phase 2 efficacy trials. Denifanstat already holds FDA Breakthrough Therapy designation for non-cirrhotic MASH with fibrosis, and positive results could support broader regulatory pathways for combination treatment in patients with cirrhosis (F4), where no approved therapies currently exist.
Business Significance
Advertisement
The initiation of this study reinforces Sagimet’s position as a clinical-stage biopharma innovator in metabolic and fibrotic diseases. If successful, the combination strategy may expand the company’s pipeline value, create partnership opportunities, and strengthen investor confidence in a market where effective therapies for MASH represent a multi-billion-dollar commercial opportunity.
Patients’ Significance
For patients with MASH, particularly those with stage F4 cirrhosis, treatment options remain limited to none. The potential availability of a synergistic oral combination therapy could provide improved outcomes, including reduced progression to liver failure, hepatocellular carcinoma, and need for transplantation, significantly improving survival and quality of life.
Policy Significance
The trial reflects the importance of health policy frameworks that incentivize innovation in liver diseases, including orphan and breakthrough designations. With MASH estimated to affect over 265 million people worldwide, supporting accelerated development pathways will be critical to address this rising global health challenge.
Sagimet’s launch of the Phase 1 trial for denifanstat and resmetirom marks a promising step toward addressing the unmet needs of MASH patients. With synergistic science, regulatory backing, and patient-centered goals, the study has potential to advance a new therapeutic standard for one of the world’s fastest-growing liver diseases.
Source : Sagimet Biosciences Press Release
